Lupin Limited has informed the Exchange regarding a press release dated December 18, 2025, titled "Lupin Signs Exclusive Licensing Agreement with Neopharmed for GastroenterologyBrand Plasil® in the Philippines and Brazil".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has signed an exclusive licensing deal with Neopharmed for its gastroenterology brand Plasil® in the Philippines and Brazil. Under the agreement, Neopharmed will have exclusive rights to market and distribute Plasil® in these two markets, while Lupin likely retains manufacturing or supply involvement. Plasil® is an established brand used for treating gastrointestinal disorders. The move allows Lupin to expand the brand's reach in emerging markets without bearing direct marketing and distribution costs in those regions.
This is a measured international expansion move that adds a new revenue stream from licensing royalties/supply income without significant capital outlay. For shareholders, it is mildly positive — strengthens Lupin's emerging markets footprint — but the near-term financial impact is likely small given the limited geography of the deal.